
FDA Drug Approvals Q1 2025
Hematology/Oncology Datroway (datopotamab deruxtecan) Datopotamab deruxtecan is a Trop-2-directed antibody and topoisomerase inhibitor conjugate. It is indicated for unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth …